Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AbATE: Teplizumab in New Onset Type 1 Diabetes
NCT00129259Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2005
- Primary completion
- Mar 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of teplizumab in type 1 diabetes mellitus (T1D), sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2005; status: completed.
02
Drugs
teplizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00129259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129259.